A CD19/CD3 bispecific TandAb, AFM11, recruits T cells to potently and safely kill CD19+ tumor cells in pre-clinical models
Reusch et al.
PEGS 2014
Reusch et al.
PEGS 2014
Reusch et al.
MAbs. 2014 Mar 26;6(3).
Reiners et al.
Mol Ther. 2013 Apr;21(4):895-903. doi: 10.1038/mt.2013.14. Epub 2013 Mar 5./.
Pörtner et al.
Cancer Immunol Immunother. 2012 Oct;61(10):1869-75
McAleese F, Eser M.
Future Oncol. 2012 Jun;8(6):687-95.
Authors: Le Gall F and Little M., Editor: Melvyn Little
Publ. Cambridge University Press, 2009